US Court Deals Blow to Novo Nordisk in Medicare Pricing Dispute
Published on 10/09/2025 at 17:36 | Redaktion boerse-global.de
A federal appeals court in the United States has unanimously rejected Novo Nordisk’s legal challenge against the Medicare drug price negotiation program, marking a significant regulatory defeat for the Danish pharmaceutical giant. This ruling strengthens the government’s position and potentially paves the way for substantial price reductions on the company’s top-selling diabetes and obesity medications.
The court’s decision affirms the US government’s authority to group medications sharing the same active ingredient for pricing negotiations. This proved critical for Novo Nordisk’s portfolio. Six of the company’s insulin products were already classified as a single product in the initial negotiation round.
More consequentially, for the upcoming second round, the Centers for Medicare & Medicaid... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
